Core Viewpoint - Vivani Medical, Inc. is advancing its NPM-139 semaglutide implant program, aiming for Wegovy-level efficacy with less frequent administration, and plans to initiate a Phase 1 clinical study in the first half of 2026, pending regulatory clearance [1][2][3] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [5] - The company is developing a portfolio of GLP-1 based implants targeting chronic weight management and other metabolic diseases, including type 2 diabetes [5] Clinical Development Plans - The Phase 1 study of NPM-139 will assess safety, tolerability, and pharmacokinetics in obese or overweight subjects, with a control arm of low-dose Wegovy injections [3][4] - A Phase 2 study is planned to follow the Phase 1 study, pending results, to evaluate the effects of the semaglutide implant on weight management over 4 to 6 months [4] Market Potential - The GLP-1 market for weight management is experiencing significant growth due to unmet medical needs and improved safety and efficacy profiles of current GLP-1 options compared to previous obesity treatments [2] - NPM-139 is expected to differentiate itself by offering a convenient administration schedule of once or twice a year, potentially improving patient adherence and tolerability [2][6]

Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the 2025 BIO International Convention, highlighting its potential to improve medication adherence and patient outcomes in chronic disease management [1][4]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants using its proprietary NanoPortal™ technology [3]. - The company's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant aimed at chronic weight management for obese or overweight individuals [1][3]. - Vivani's emerging pipeline includes NPM-139 (semaglutide implant) and NPM-119, both designed for chronic weight management and type 2 diabetes treatment, respectively [3]. Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4]. - The current GLP-1 landscape features over 50 new molecular entities in clinical development, with Vivani's differentiated portfolio of miniature implants positioned as a promising therapeutic option [4].